Forum Home | Log in | Signup | My Page | Rules | FAQ | Boards | Members | Search
« POPE IV Home | Email msg. | Reply to msg. | Post new | Board info. Previous | Home | Next

Re: Sarepta Therapeutics FDA Panel Live Blog 

By: Decomposed in POPE IV | Recommend this post (2)
Mon, 25 Apr 16 11:06 PM | 74 view(s)
Boardmark this board | POPES NEW and Improved Real Board 		Msg. 05953 of 47202
(This msg. is a reply to 05952 by Decomposed)
Jump:
Jump to board:
Jump to msg. #

The FDA panel is going to make some sort of a decision this evening. Trading is currently halted.

I'm optimistic, but this could go either way. *IF* the decision is positive, this billion dollar company will have an additional $500 million in annual sales. The reward justifies the risk. I hope you guys have some.

Sarepta's eteplirsen *IS* safe. The only competing product was just shot down because it wasn't. The question is . . . is there enough proof that it works? Given that the victims are children and that there is little else that can be done for them, I think that marginal evidence of efficacy should still result in a favorable decision.

Now I'm waiting. Tick . . . tick . . . tick. 




Avatar

Gold is $1,581/oz today. When it hits $2,000, it will be up 26.5%. Let's see how long that takes. - De 3/11/2013 - ANSWER: 7 Years, 5 Months


 - - - - -
View Replies (1) »



» You can also:
- - - - -
The above is a reply to the following message:
Sarepta Therapeutics FDA Panel Live Blog
By: Decomposed in POPE IV
Mon, 25 Apr 16 10:29 PM 		Msg. 05952 of 47202

Sarepta Therapeutics FDA Panel Live Blog

By Adam Feuerstein
04/25/16

http://www.thestreet.com/story/13541457/1/sarepta-therapeutics-fda-panel-live-blog.html

Monday is a crucial day for Sarepta Therapeutics (SRPT - Get Report) .

The live blog above is tracking all the action at a U.S. Food and Drug Administration advisory committee meeting, convened to review eteplirsen, Sarepta's experimental drug for the treatment of Duchenne muscular dystrophy.

TheStreet Senior Columnist Adam Feuerstein is providing live coverage and analysis of the Sarepta FDA advisory panel as it happens near Washington, D.C.

At the end of Monday's meeting, a panel of 13 independent experts will vote on a series of questions which will provide recommendation to the FDA on whether or not eteplirsen should be approved, or not.

Sarepta shares are halted for trading while the advisory panel is in session. The stock last traded Friday at $14.95.

« POPE IV Home | Email msg. | Reply to msg. | Post new | Board info. Previous | Home | Next